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CLINICAL REVIEW ARTICLE
A Systematic Review on Inﬂiximab and Adalimumab Drug
Monitoring: Levels, Clinical Outcomes and Assays
Filipa Silva-Ferreira, MD,*,† Joana Afonso, MSc,*,† Pedro Pinto-Lopes, MD,‡
and Fernando Magro, MD, PhD*,†,§on behalf of GEDII (Portuguese IBD Study Group)
Background: Immunogenicity to therapeutic proteins has been linked to loss of response by a large percentage of patients taking anti–tumor necrosis
factor-alpha agents. Drug monitoring can be extremely useful, allowing physicians to adjust the therapeutic scheme individually. This article aims to
systematically review the published data with respect to cutoff levels of inﬂiximab (IFX) and adalimumab (ADA) and relate them to the methodology
adopted for quantiﬁcation of IFX and ADA levels and clinical outcomes.
Methods: The PubMed database was searched to identify studies focusing on the association between IFX or ADA cutoff levels and clinical outcomes
in patients with inﬂammatory bowel disease.
Results: Of the 1654 articles initially selected by queries, 20 were included. A receiver operating characteristic curve analysis was performed to identify
cutoff levels of IFX or ADA that correlated with a clinical outcome, but only 6 studies performed the same analysis for antidrug antibody levels. Cutoff
levels were different between studies. The methodology chosen for level quantiﬁcations, clinical outcomes, and sample size and characteristics were also
different. Nevertheless, measurement of drug levels should be performed during maintenance, and with loss of response, with persistent high levels of
C-reactive protein, and when mucosal lesions are still present. In these scenarios, drug and antidrug levels were correlated with clinical outcomes.
Conclusions: Concerning drug levels monitoring any methodology is adequate. With respect to antidrug antibody levels, it will be necessary to deﬁne
a gold standard method or to establish different cutoff levels for different methodologies.
(Inﬂamm Bowel Dis 2016;0:1–13)
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I nﬂiximab (IFX) and adalimumab (ADA) are antitumor necrosisfactor-alpha (TNFa) agents that have changed the clinical
course of many autoimmune diseases such as inﬂammatory bowel
disease (IBD), psoriasis, and rheumatoid arthritis. These agents
have been successfully used in the past decades to treat patients
with IBD, even in those who were refractory to conventional
therapy.1–5 Introduction of these agents to the drug
market allowed physicians to aim for more than clinical remis-
sion, as these new drugs were proven to induce endoscopic remis-
sion and mucosa healing in patients with either Crohn’s disease
(CD) or ulcerative colitis (UC).6–8 Despite this, up to 70% of
patients lose responsiveness over time.9 Many mechanisms may
be involved in the loss of response, but immunogenicity to the
antibody itself is so far the best studied.10 The presence of anti-
bodies to IFX (ATIs) in patients’ serum was associated with a 3-
fold higher risk of loss of response than in patients who did not
have ATIs in their serum.9 Although ADA is a fully human
monoclonal antibody drug, immunogenicity to this drug has
already been described and a negative correlation between the
presence of antibodies to ADA (ATA) and ADA trough levels
(TLs) was demonstrated.11 However, the inﬂuence of ADA levels
in clinical and endoscopic remission is not well established yet.
When patients lose response to anti-TNFa agents, their
physicians have roughly 4 options: (1) dose escalation, (2) addi-
tion of an immunomodulator, (3) change to another class of drugs,
or (4) change to another anti-TNF agent.12–17 Currently, physi-
cians have to empirically decide since measurement of drug and
antidrug antibody levels is not yet used in daily practice. Many
authors have highlighted the importance of knowing drug and
antidrug antibody levels to better adjust the therapeutic scheme.
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Nonetheless, most authors emphasize the need to ﬁnd a valid
assay, especially to measure antidrug antibodies and to set cutoff
levels to help in decision-making.18–20 The aim of this article was
to systematically review the published data with respect to IFX
and ADA levels, the methodology applied, and the relationship
with clinical outcomes.
MATERIALS AND METHODS
A systematic review focusing on the association between
IFX, ADA TL, ATIs, ATAs, and clinical outcomes in patients
with IBD was performed.
Search Strategy
A literature search was performed, through July 2015, using
the PubMed database with the following keywords and Medical
Subject Headings (MeSH) terms: “{(adalimumab[All ﬁelds]) OR
(inﬂiximab[All ﬁelds])} AND {(inﬂammatory bowel disease
[MeSH Terms]) OR (inﬂammatory bowel diseases[MeSH
Terms]) OR (crohn’s disease[MeSH Terms]) OR (colitis, ulcera-
tive[MeSH Terms]) OR (crohn disease[MeSH Terms])} AND
([clinical response] OR [clinical remission] OR [disease activity]
OR [clinical outcomes]).” Considering this is a hot topic, we
decided, on December 2015, to perform an additional literature
search on abstracts presented on 3 reference congresses. The
European Crohn’s and Colitis Organisation (ECCO) Website
was searched for all published abstracts related with this topic,
using the terms “inﬂiximab ifx” and “adalimumab ada”; The
United European Gastroenterology Week (UEGW) Website was
searched for abstracts from the last United European Gastroenter-
ology week in Barcelona; The Digestive Disease Week (DDW)
Website was searched for abstracts from the past 5 years, using
the terms “inﬂiximab levels” and “adalimumab levels” in title,
abstract, or keywords.
Eligibility Criteria
The inclusion criteria were: (1) articles studying the
association between IFX or ADA cutoff levels and clinical
outcomes in patients with IBD and (2) articles written in English.
We excluded studies that (1) were systematic reviews, (2)
used another anti-TNF-a agent rather than IFX or ADA, (3)
enrolled patients with other diseases rather than IBD (psoriasis,
rheumatoid arthritis), (4) only assessed the relationship between
IFX or ADA TL and clinical outcomes but did not perform
a receiver operating characteristic (ROC) curve analysis, or (5)
did not present the speciﬁcity and sensitivity values of the ROC
curve analysis. This last criterion was deﬁned so that we could
infer the accuracy of the cutoff value (i.e., a cutoff value with
a sensitivity and/or speciﬁcity of 50% would be no better at
identifying true positives than ﬂipping a coin). It was not applied
to abstracts found on ECCO, UEGW, or DDW databases.
Study Selection and Data Collection Process
Studies were screened and selected by 2 reviewers. First, all
titles and abstracts were read and the inclusion and exclusion
criteria were applied. Second, the articles considered for inclusion
after selection by title/abstract reading were read fully and the
inclusion and exclusion criteria were applied again. The data
collected from each study were: the type of study and location,
number of patients enrolled, and the type of IBD, deﬁnitions of
clinical outcomes, antidrug antibodies incidence, type of assay
used to measure IFX/ADA and ATIs/ATAs serum levels, and the
results from the ROC curve analysis (cutoff levels and speciﬁcity
and sensitivity values), except for the studies obtained in ECCO,
UEGW, or DDW databases. In these studies, we have only had
access to the abstract. A quality assessment was performed using
a qualitative classiﬁcation of the risk of bias. We used a 4-item
classiﬁcation based on the Meta-analysis of Observational Studies
in Epidemiology checklist.21 The items were chosen based on the
factors that can incorporate bias, i.e., inclusion and exclusion
criteria, justiﬁcation of the cohort (eligibility criteria, sources
and methods of selecting participants, and the methods used to
describe follow-up), the type of disease (if they pointed out
whether the patients included had CD or UC), and the assay used
to measure drug and antidrug antibody levels (Fig. 1).
RESULTS
Search and Study Selection
A total of 1237 articles were identiﬁed with our query (Fig.
2). Of these, 1160 were excluded by title and/or abstract alone,
mainly because they did not study the association between IFX or
ADA TL and clinical outcomes. Therefore, 77 articles were con-
sidered for full text analysis and after that 13 were included in our
systematic review (Fig. 2). Two additional articles were included
after searching those related to the 13 articles selected by
query.22,23 From the search on ECCO, UEGW, and DDW abstract
databases, 417 abstracts were found but only 5 were included,
according to the inclusion criteria previously deﬁned (Fig. 3).
Description of Studies
Of the 20 studies included, all but one24 were conducted in
adult patients. One study25 only involved patients with UC, 11
studies6,11,22,23,26–33 only encompassed patients with CD and 7 stud-
ies pertained to patients with either UC or CD.8,24,34–38 Fifteen of
the 19 studies involved IFX maintenance therapy6,8,22,24–28,30–35,37
(Table 1), whereas the other 4 involved ADA maintenance therapy
(Table 2).11,23,29,36 One study encompassed patients from both regi-
mens, IFX and ADA maintenance therapy.38 Seven studies did not
report information about the incidence of ATIs,25,29,31–33,38,39 and
only 6 performed an ROC curve analysis to ﬁnd a cutoff value for
ATI22,32,34,35,37 or ATA11 levels.
In 6 studies, the clinical outcome was “clinical remis-
sion”8,11,22,24,28,36 usually assessed by the Harvey-Bradshaw
Index–Mayo score and/or C-reactive protein (CRP) levels. In 4
studies, the outcome was “loss of response,”26,32,35,37 deﬁned as an
initial good clinical response to IFX induction treatment followed
by a loss of clinical response to IFX during maintenance treatment
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leading to discontinuation of the drug. For Adedokun et al,25 the
endpoint was the “clinical response” deﬁned as a decrease from
the baseline in the total Mayo score of$3 points and at least 30%,
and a decrease in the subscore for rectal bleeding of $1 or an
absolute subscore for rectal bleeding of 0 or 1. For Levesque
et al,30 there were 2 endpoints which were an “increase in CD
activity index $70” and an “increase in CRP $ 5 mg/L.” Imaeda
et al6 deﬁned 2 endpoints for IFX, including “mucosa healing,”
meaning an endoscopic score of 0 or 1, and “CRP # 0.3 mg/L,”
whereas for ADA,29 they only used “CRP#0.3 mg/L.” Four more
studies deﬁned “mucosa healing” as the endpoint of inter-
est.23,31,33,38 Cornillie et al27 deﬁned clinical outcome as a “sus-
tained response at week 54,” which was expressed as clinical
remission based on the relevant disease activity index at week
54, in the absence of any dose intensiﬁcation during IFX main-
tenance therapy. Paul et al37 also deﬁned 2 endpoints: “loss of
response” and “absence of clinical remission.” Vande Casteele
et al34 described 3 endpoints which were “ATI formation,”
“IFX discontinuation,” and “unsuccessful intervention.” The
intervention (change in therapy) was considered successful if, at
the second infusion after the intervention, the symptoms had dis-
appeared and CRP, if elevated before the intervention, had
FIGURE 1. Summary of risk of bias.
FIGURE 2. Data collection process.
FIGURE 3. Data collection process.
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TABLE 1. IFX Trough Levels and Antidrug Antibodies Cutoff, Methodology and Clinical Outcomes
Authors Study Design Population Regimen Country Time Point
Echarri et al28 — 36 Adults with CD IFX Spain W0, W6, W14, W30
Roblin et al32 Prospective cohort 119 Adults with CD IFX France Trough level
Ungar et al38 Retrospective cross-
sectional
78 Adults with IBD IFX Israel No data
Adedokun et al, 201425 Observational (post-hoc
ACT1-2)
454 Adults with UC IFX; induction regimen
followed by maintenance
therapy
globally W8
W30
W54
Cornillie et al27 Observational (analyses of
ACCENT I)
573 Adults with CD IFX; induction regimen
followed by maintenance
therapy
North America, Europe,
Israel
W14
Levesque et al30 Prospective cohort 327 Adults with CD IFX; maintenance therapy Canada W8
Marits et al8 Retrospective 63 Adults with CD, 15
adults with UC, 1 adult
with U-IBD
IFX Sweden Just before next infusion
Papamichail et al, 201531 Retrospective 101 adults with CD IFX Belgium W 0, 2, 6, 14
Singh et al24 Prospective cohort 58 pediatric patients (,21
years) with CD and UC
IFX; induction regimen
followed by maintenance
therapy
USA W14
Tang et al33 No 15 adults with CD IFX China No data
Vande Casteele et al22 Observational 483 adults with CD IFX; maintenance therapy Belgium Canada No data
Bortlik et al26 Retrospective 84 adults with CD IFX Czech Republic W14–22
Imaeda et al, 20146 Prospective cohort 65 adults with CD IFX; maintenance therapy Japan Just before next infusion
Paul et al37 Prospective cohort 103 adults with IBD IFX; maintenance therapy France Just before next infusion
Vande Casteele et al34 Retrospective 64 adults with CD, 26 adults
with UC
IFX Belgium Just before next infusion
Steenholdt et al35 Retrospective 85 adults with CD, 21 adults
with UC
IFX Denmark Just before next infusion
Authors
Drug Antidrug antibodies
EndpointMethod Cutoff, mg/mL Spec/Sens, % Method Incidence, n (%) Cutoff Spec/Sens, %
Echarri et al28 ELISA .3 (w6) No ELISA No (26) No No Good response and
sustained
remission
Roblin et al32 ELISA (commercial
kit, Theradiag)
,2 No ELISA No .20 ng/mL No Loss of response
Ungar et al38 No .5 85/— No No No No Mucosa healing
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TABLE 1 (Continued )
Authors
Drug Antidrug antibodies
EndpointMethod Cutoff, mg/mL Spec/Sens, % Method Incidence, n (%) Cutoff Spec/Sens, %
Adedokun et al,
201425
Classic ELISA .41 (w8) 62/63 (w8) Bridging ELISA No No No Clinical response
.3.7 (w30) 71/65 (w30)
.1.7 (w54) 64/89 (w54)
Cornillie et al27 Classic ELISA $3.5 78/64 Bridging ELISA ATI+ ¼ 2 (9) No No Sustained response
at w54
Levesque et al30 HMSA (commercial
kit, Prometheus
Laboratories)
#2.8–4.6 (a) 68/61 (a) HMSA (commercial
kit)
ATI+ ¼ 57 (18) No No (a) Increased CDAI
$70; (b) Increased
CRP $5 mg/L
#2.7–2.8 (b) 74/64 (b)
Marits et al8 Classic ELISA .4.1 (CD) 44/87 Inhibition ELISA ATI+ ¼ 22 (79); ATI
transient ¼ 4 (18)
No No Remission (HBI-
Mayo and CRP)
Papamichail et al,
201531
ELISA .22.5 (w2) No No No No No Short-term mucosa
healing.12.8 (w6)
Singh et al24 Classic ELISA and
HMSA
(Prometheus
Laboratories)
$5 85/50 Bridging ELISA and
HMSA
(Prometheus
Laboratories)
No (10 at w14), no
(26 at w54)
No No Week 54 persistent
remission$7 100/33
Tang et al33 No .4.87 77/88 No No No No Mucosa healing
Vande Casteele et
al22
HMSA (commercial
kit)
.2.79 77.6/52.5 HMSA (commercial
kit)
23.7% (IFX2/ATI2
¼ 6.5%; IFX
+/ATI2 ¼
69.8%; IFX2/
ATI+ ¼ 16.4%;
IFX+/ATI+ ¼
7.3%)
, 3.15 U/mL 87.4/38.0 Remission (CRP # 5
mg/L)
Bortlik et al26 Classic ELISA (Q-
INFLIXI, Matriks
Biotek)
,3 62/70 Bridging ELISA
(commercial kit)
ATI+ ¼ 14 (17),
ATI2 ¼ 24 (28),
ATI inconclusive
¼ 46 (55)
No No Loss of response at 1
year using IFX
Imaeda et al, 20146 Classic ELISA .4 (a) 70/71 (a) ELISA (+acid
dissociation and
immunoafﬁnity
crhomatography)
No No No (a) Mucosa healing
.0.6 (b) 62/73 (b) (b) CRP , 0.3 mg/L
Paul et al37 ELISA (commercial
kit, Theradiag)
,2 (a) 82.3/76 Bridging ELISA
(commercial kit)
ATI+ ¼ 34 (32.8),
CD ¼ 25.4%, UC
¼ 41.5%,a ATI+
¼ 65.3%b
.200 ng/mL (b) 93.5/22.0 (a) Absence of
clinical remission
(b) Loss of response.
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decreased by .50% than the value at the time of loss of clinical
response. Quality assessment was limited in those cases to which
we only had access to the abstract.28,31–33,38 Taking into consider-
ation the other studies, all but 4 had suitable inclusion and exclu-
sion criteria,8,24,29,36 and all papers indicated the type of IBD and
the assay used to measured drug and antidrug antibody levels.
Assays Used to Measure Drug and Antidrug
Antibody Levels
One aspect that should be taken into consideration when
analyzing drug TL and antidrug antibody levels is the assay used
to measure them. All but 3 of the included works measured IFX or
ADA TL using classic enzyme-linked immunosorbent assay
(ELISA).6,8,11,24–29,31,32,34,36,37 Zittan et al,23 Levesque et al,30 and
Vande Casteele et al22 used a homogeneous mobility shift assay
(HMSA), whereas Steenholdt et al35 used a ﬂuid-phase radioim-
munoassay (ﬂuid-phase RIA). Singh et al24 tested 2 methodolo-
gies, the classic ELISA and HMSA.
Regarding antidrug antibody measurements, 7 studies used
bridging ELISA, either via home-made assays or commercial
kits.25–28,32,36,37 Mazor et al11 applied an adaptation of the anti-
human lambda chain-based ELISA. In 2 studies by Imaeda et al,
ATI6 and ATA29 levels were also measured with ELISA, but
samples were previously treated with acid in order to dissociate
immune complexes. Other methods were used, namely HMSA,23
ﬂuid-phase RIA,35 and inhibition ELISA.8 Singh et al24 tested 2
methodologies, bridging ELISA and HMSA. Figure 4 displays all
methodologies used.
Inﬂiximab Levels
By Week of Measurement
Of the 16 IFX studies, 7 speciﬁed the time point
measurement24–27,30: one measured drug levels at week 2,31 2 at
week 6,28,31 2 at week 8,25,30 3 at week 14,24,26,27 1 at week 22,26
and 125 also measured IFX levels at weeks 30 and 54. Others only
indicated that measurements were made before each infusion, thus
representing drug TL.6,8,11,29,34,35,37
In Papamichaiel et al,31 2 cutoff levels were proposed
(Table 1), both correlating with short-term mucosa healing,
but after multiple logistic regression analysis, only IFX levels
.12.8 mg/mL at week 6 were retained as an independent factor
to predict short-term mucosa healing (OR: 3.6, P ¼ 0.004).
Echarri et al28 presented a largely different cutoff level for
the same time point. They suggest that IFX levels .3 mg/mL
at week 6 had a positive-predictive value for “good response
and sustained remission” of .90%. Adedokun et al25 showed
that IFX levels .41 mg/mL at week 8 correlated with clinical
response with a speciﬁcity of 62% and a sensitivity of 63%
(Table 1). The median serum IFX concentration was signiﬁ-
cantly higher at week 8 in patients with clinical response or
mucosal healing during induction than those not achieving
these endpoints. Levesque et al30 found a different cutoff:
a mean IFX trough concentration ,3 mg/mL at week 8 wasTA
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TABLE 2. ADA Trough Levels and Antidrug Antibodies Cutoff, Methodology and Clinical Outcomes
Authors Study Design Population Regimen Country Time point
Drug
Method Cutoff, mg/mL Spec/Sens, %
Zittan et al, 201623 Observational 60 Adults with CD ADA Canada — HMSA (commercial
kit, Prometheus
Laboratories)
8.14 76.0/91.4
Ungar et al38 Retrospective, cross-
sectional
67 Adults with IBD ADA Israel — — .7.1 85/—
Mazor et al11 Observational, cross-
sectional
71 Adults with CD ADA Israel Just before next
infusion
Classic ELISA .5.85 (a) 70.6/68
Roblin et al36 Observational cross-
sectional
40 Adults with IBD ADA; maintenance
therapy
France W22 ELISA (commercial
kit, Theradiag)
,4.9 (a) 85/66
.4.85 (b) 67/81
Imaeda et al, 201429 Prospective cohort 40 Adults with CD ADA; maintenance
therapy
Japan Just before next
infusion
Classic ELISA .5.9 92/67
Authors
Antidrug antibodies
EndpointMethod Incidence, n (%) Cutoff Spec/Sens, %
Zittan et al, 201623 HMSA (commercial kit, Prometheus Laboratories) No (30.9)a — — Mucosa healing
Ungar et al38 — — — — Mucosa healing
Mazor et al11 (adapted) Antihuman lambda chain-based ELISA No (30.5 samples)b $ 3 mg/mL (b) 98/20.6 (a) Remission; (b) Active disease
no (12.7 samples)c
Roblin et al36 Bridging ELISA (commercial kit) 9 (22.5) No No (a) Absence of mucosa healing
(b) Clinical remission
Imaeda et al, 201429 ELISA (+acid dissociation) 35 (23) No No CRP # 0.3 mg/dL
aCutoff for ATA positivity .1 U/mL.
bCutoff for ATA positivity .1.5 mg/mL-eq.
cCutoff for ATA positivity .3 mg/mL-eq.
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signiﬁcantly associated with a $70-point increase in the mean
total CD activity index score between infusions (P , 0.001).
In measurements performed at weeks 14 and/or 22, cutoff
values varied from ,326 to $7 mg/mL24 (Table 1). Patients with
TL .3 mg/mL at weeks 14 and/or 22 had an approximately 66%
lower likelihood to lose their response to IFX than those with
subtherapeutic levels.26 These ﬁndings are similar to data from
the post-hoc analysis of the ACCENT I trial (A Crohn’s Disease
Clinical Trial Evaluating Inﬂiximab in a New Long-term Treat-
ment Regimen I),27 which found that an IFX level .3.5 mg/mL at
week 14 was a good predictor of sustained response at week 54.
Patients with sustained response to scheduled maintenance IFX at
5 mg/kg had higher median IFX TL than those who lost response
during the 54 weeks follow-up (4.0 versus 1.9 mg/mL, P ¼
0.0331). Adedokun et al25 also measured IFX levels at weeks
30 and 54 and the levels, related with clinical response, were
3.7 and 1.7 mg/mL, respectively (Table 1). They suggested that
more weight should be given to the threshold estimate at week 30
(3.7 mg/mL) because it was most representative of the steady-state
trough concentration for both Active Ulcerative Colitis Trial stud-
ies. Therefore, patients with IFX TL .3.7 mg/mL at week 30 are
more than twice as likely to have clinical response than patients
with IFX TL ,3.7 mg/mL.
Mucosa Healing
Imaeda et al6 found that IFX TL .4 mg/mL was a good
predictor of mucosa healing (Table 1). The authors also showed
that the deterioration of the endoscopic ﬁndings was signiﬁcantly
associated with lower IFX TL. Two abstracts reported similar
cutoff levels.33,38 In both of them, IFX levels were signiﬁcantly
higher in the mucosal healing group than in patients with active
disease (4.3 versus 1.7 mg/mL, P ¼ 0.000238).
Loss of Response
Steenholdt et al35 showed that IFX TL ,0.5 in CD and
,0.8 in UC were good predictors of loss of response. IFX TL
were signiﬁcantly higher in both patients with CD and patients
with UC who had maintained response to IFX compared with
those who had lost response (median 2.8 mg/mL versus median
0 mg/mL, for CD; and 3.8 mg/mL versus 0 mg/mL for UC). High-
er levels were identiﬁed by Bortlik et al26 (,3 mg/mL) and Roblin
et al32 (,2 mg/mL).
Biomarkers
Imaeda et al6 showed that IFX levels .0.6 mg/mL could
predict normalized CRP levels (,3 mg/dL) with good sensitivity
and speciﬁcity (Table 1). C-reactive protein levels were signiﬁ-
cantly higher in the nonmucosal healing group than in the muco-
sal healing group (0.09 versus 1.32 mg/dL). Levesque et al30
showed that IFX concentrations ,2.7 to 2.8 mg/mL predicted
serum CRP levels .5 mg/L. Therefore, they suggested that
a mean IFX trough concentration ,3 mg/mL at week 8 was
signiﬁcantly associated with a higher probability for serum CRP
concentrations .5 mg/L at that time point. In a study by Vande
Casteele et al,22 an IFX TL .2.79 mg/mL was considered to be
a good predictor of CRP ,5 mg/L, meaning that patients with
IFX levels,2.79 mg/mL in a “current” sample were at higher risk
of not achieving remission, deﬁned as CRP ,5 mg/L.
Adalimumab Levels
ADA information is sparse. Imaeda et al29 evaluated 40
adults with CD and performed an ROC curve analysis to identify
threshold levels of ADA that could predict normalized CRP levels
(i.e., CRP # 3 mg/dL). ADA levels .5.9 mg/mL predicted nor-
malized CRP with high speciﬁcity (Table 2). Mazor et al11 and
FIGURE 4. Methodologies for antidrug antibodies quantiﬁcation.
Silva-Ferreira et al Inﬂamm Bowel Dis  Volume 0, Number 0, Month 2016
8 | www.ibdjournal.org
Copyright © 2016 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
Roblin et al36 conducted cross-sectional studies in patients taking
ADA maintenance therapy; Mazor et al11 enrolled patients with
CD and Roblin et al36 enrolled patients with CD or UC. In the
study by Mazor et al, ADA TL .5.85 mg/mL predicted remission
with a speciﬁcity and sensitivity of 70.6% and 68.0%, respec-
tively. Roblin et al36 showed that ADA serum concentrations
,4.9 mg/mL predicted an absence of mucosa healing. The median
ADA TL was signiﬁcantly higher in cases of mucosa healing (6.5
versus 4.2 mg/mL in those without mucosa healing; P , 0.005).
Moreover, serum levels higher than 4.85 mg/mL predicted clinical
remission, deﬁned as CD activity index ,150 points or total
Mayo score ,3 (Table 2). Higher ADA TL were found in the
work by Zittan et al (14.7 mg/mL in the mucosa healing group,
versus 3.4 mg/mL in the non-MH group, P ¼ 6.25 · 1025).23
Furthermore, Zittan et al suggested that ADA TL ,8.14 mg/mL
predicted MH with high sensitivity (Table 2). In the work by
Ungar et al,38 ADA levels .7.1 mg/mL identiﬁed patients with
mucosa healing with 85% speciﬁcity. He also found that the
association between higher levels of ADA and increased rate of
mucosa healing reached a plateau at 12 mg/mL.
Incidence of ATIs and ATAs
Antidrug antibodies are described as the main cause of loss
of response to biologic drugs over time. However, the incidence
of antidrug antibodies varies signiﬁcantly between studies. Taking
into consideration those included in this systematic review, the
ATI incidence varied from 9%27 to 63.5%37 (Table 1). In Bortlik
et al,26 17% of the patients had ATIs but 55% were considered
inconclusive. Marits et al8 reported 22 out of 28 patients with
ATIs, wherein 18% of them were ATI transient, meaning that
patients presented with ATIs in their serum which at some point
disappeared. The same was reported by Vande Casteele et al,34
where 15 of the 53 patients considered with ATIs were transient
(Table 1). Vande Casteele et al22 reported an ATI incidence of
23.7%, and the authors were able to distinguish 4 groups of
patients based on ATI and IFX status (Table 1). Paul et al37
showed a global incidence of ATIs of 32.8%, considering a cutoff
for ATIs of 10 ng/mL; with a cutoff of 5 ng/mL, the incidence was
63.5%. In the pediatric setting, 10% of the patients had ATIs in
their blood at week 14, but the incidence increased to 16% at
week 54.24
Although ADA is a fully human antibody, some patients
develop ATAs. Imaeda et al29 described a 23% incidence of ATAs.
Roblin et al36 found a similar value (22.5%). In the cross-sectional
study from Mazor et al,11 12.7% of the samples had ATA levels$3
mg/mL; when a cutoff of $1.5 mg/mL was established, the inci-
dence rose to 30.5% (Table 2). Zittan et al23 described an ATA
incidence of 30.9%, using a cutoff of .1 U/mL.
Cutoff Levels of ATIs and ATAs
Only 5 studies11,22,34,35,37 performed an ROC curve analysis
to identify threshold levels for antidrug antibodies. Steenholdt
et al35 reported that ATI levels, measured with ﬂuid-phase RIA,
.10 U/mL in patients with CD predicted “loss of clinical
response” with a speciﬁcity of 90% and sensitivity of 81%. In
the subgroup of patients with UC, the speciﬁcity was higher
(Table 1). ATI were signiﬁcantly lower in both patients with
CD and patients with UC who had maintained response to IFX
compared with those who had lost response (median 0 U/mL
versus median 35 U/mL for CD, and median 0 U/mL versus
median 85 U/mL for UC).
Paul et al37 also performed an ROC curve analysis using
“loss of response” as the target clinical outcome. The authors
suggested that ATI levels .200 ng/mL, assessed by the ELISA
assay, predicted loss of response with a high speciﬁcity but with
a low sensitivity (Table 1). A combined analysis was also per-
formed on patients with CD with IFX levels ,2 mg/mL and ATI
levels ,200 ng/mL. The ATIs predicted clinical remission with
a high speciﬁcity and sensitivity (Table 1); patients with UC
showed higher speciﬁcity (100%) but lower sensitivity (70%).
The same analysis using “mucosa healing” as the clinical outcome
was also supplied (Table 1). An ROC curve analysis for a thresh-
old .9.1 U/mL at the time of loss of response predicted an
“unsuccessful intervention” with a speciﬁcity of 82% and a sensi-
tivity of 65%.34 Therefore, patients having ATI TL .9.1 U/mL at
the time of loss of response had a likelihood ratio of 3.6 for an
unsuccessful intervention. It was also reported that patients with
ATI levels ,3.15 U/mL had a higher probability of being in
remission.21
With regard to ADA, Mazor et al11 suggested that a cutoff
level $3 mg/mL, when using an adapted anti-human lambda
chained-based ELISA assay, predicted active disease with high
speciﬁcity but low sensitivity (Table 2). The authors showed
a negative correlation between ADA drug levels and ATA levels
and found that for patients with ATA levels $3 mg/mL-eq, the
maximal ADA level was only 0.5 mg/mL.
DISCUSSION
The importance of measuring drug levels and antidrug
antibody levels to adjust therapy is undisputable. The major
hindrance to its implementation in daily clinical practice is the
lack of a universally valid assay and the absence of a cutoff level
clearly related with a clinical outcome. One cannot easily compare
results from different studies, as they use distinct assays that have
different limitations and lower limits of quantiﬁcation.
Regarding the measurement of IFX levels, classic ELISA
is the methodology most frequently used, but other methods are
available, such as HMSA and ﬂuid-phase RIA. Studies40–42 that
have compared performance of different methods to measure
drug levels have concluded the same; there is a good qualitative
correlation between different assays (e.g., IFX detection rates of
76% with ELISA and 82% with RIA42). Furthermore, in some
cases, there is a good quantitative correlation (e.g., ELISA and
RIA, R2 ¼ 0.98, P ¼ 0.00140; ELISA and RIA, Pearson r ¼
0.91, P , 0.000141) but not a perfect agreement on drug con-
centrations (e.g., maximum difference of 1.41 mg/mL between
ELISA and RIA40), and this emphasizes the importance of
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establishing different cutoff levels according to the methodology
used. The threshold levels assessed by ROC curve analysis were
quite different between the studies. This can be due to (1) dif-
ferent methodology (even using the same principle, such as
bridging ELISA, home-made ELISA, and commercial kits), (2)
different study design and sample characteristics, and/or (3) dif-
ferent endpoints. This heterogeneity justiﬁes the obstacle to per-
form a meta-analysis. A systematic review and meta-analysis
was recently published on this topic and suggested a cutoff level
of 2 mg/mL to predict remission (RR ¼ 2.9, 95% conﬁdence
interval, 1.8–4.7, P , 0.001), but there was a high statistical
heterogeneity (I2 ¼ 88%).43 However, TL were always associ-
ated with a better clinical endpoint: clinical remission, mucosa
healing, normalized CRP, or loss of response. Our review em-
phasizes the importance of measuring drug levels during main-
tenance therapy as well as in cases of loss of response, cases
with persistent high levels of CRP, and when mucosal lesions
are still present. In the induction phase, the only study reported
did not show any advantage of measuring IFX at 2 weeks
because this corresponded to the loading period and it was not
possible to differentiate responders from nonresponders. How-
ever, at weeks 8, 14, and 30, the different studies found signif-
icant differences between responders and nonresponders, and
one of these time periods should be chosen by clinicians for
strategic therapeutic decisions, namely increasing drug dose or
addition of 1 immunomodulatory drug. Active Ulcerative Colitis
Trial subanalysis suggested week 30 is ideal and argued that this
time corresponds to the steady state of the drug. Two studies
(TAILORIX44 and TAXIT45) have concluded that in mainte-
nance phase, concentration-based dose adjustment was not supe-
rior to dose adjustment based on symptoms alone. However,
TAXIT trial also showed that patients in the “clinically based
dosing” group had more ﬂares during the course of treatment
than those in the “concentration-based dosing” group.
Overall, there is evidence for determining drug levels in
weeks 6, 14, 22, 30, and 54. During maintenance, therapeutic
drug monitoring should be considered in case of loss of response,
mucosal ulceration, and elevated biomarkers, such as CRP and
fecal calprotectin (Fig. 5).
Figure 6 shows how therapeutic drug monitoring may be
used to highlight factors inﬂuencing loss of response. Two
branches are schematized: for patients with loss of response and
high levels of drug (pink branche) and for patients with loss of
response and low drug levels (green branche). Pharmacodynamic,
pharmacokinetic, and immunogenicity factors may be identiﬁed
and help clinicians to handle therapeutic decisions.
All methodologies available (ELISA, HMSA, ﬂuid-phase
RIA) seem qualitatively equivalent, so either one can be used to
monitor drug levels. However, the clinician should take into
consideration that there are disagreements on IFX concentration
between assays, therefore for each patient, drug levels should be
always measured with the same assay. Concerning antidrug
antibody levels, the variability among methods is more signiﬁ-
cant. Enzyme-linked immunosorbent assay (ELISA) is the
methodology most frequently used; however, not all ELISAs
use the same principle. A bridging ELISA, or double antigen
ELISA, uses the drug, in this case, IFX or ADA as the captured
antigen and as the detection antibody. Consequently, this method
is susceptible to several limitations, namely false-positive results,
caused by rheumatoid factors or activated complement fragments
that cross-bind the drug’s fragment crystallizable region. False-
negative results are due to the assay’s inability to detect mono-
valent immunoglobulin G4 (IgG4) and antidrug antibodies in the
presence of the drug. This method was used by 6 of the studies
included in this systematic review.24–27,36,37 Since this assay has
no sensitivity to detect antidrug antibodies in the presence of the
drug, some of the studies did not measure antidrug antibodies if
there were drug levels in the serum and considered those samples
FIGURE 5. Time points for drug level determination.
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as “ATI inconclusive.” Cornillie et al27 considered samples that
had IFX levels .0.1 mg/mL as “ATI inconclusive,” whereas
Bortlik et al26 only considered samples that had IFX levels .3
mg/mL as “ATI inconclusive.” Given that half of the patients in
clinical trials had the drug in their serum, the use of a bridging
ELISA for anti-IFX detection may lead to serious bias. This must
be taken into consideration when one tries to draw conclusions
about the therapeutic importance of ATIs using bridging
methodology.35
We should also keep in mind that study populations and
study designs were different. Some included only patients with
CD or UC, whereas others comprised both types of patients; some
were prospective cohorts while others were cross-sectional studies
or post-hoc analyses of controlled trials. These differences can
explain why the incidence of antidrug antibodies was so varied
between them, even when using the same assay. For example,
both studies from Cornillie et al27 and Paul et al37 used a bridging
ELISA to measure antidrug antibodies but the incidence of ATI
positivity was 9% and 32.8%, respectively. This could be ex-
plained by the fact that the ﬁrst study was a post-hoc analysis
of the ACCENT I trial that enrolled 573 adult patients with CD,
whereas the second was a prospective cohort with 103 adults with
CD or UC.
Kopylov et al46 developed a different ELISA method, anti-
human lambda chain-based ELISA, to overcome the false-
negative results associated with the presence of the drug. The
authors took advantage of the fact that antidrug antibodies have
a lambda light chain, whereas the drug has a kappa light chain,
and they used an anti-lambda antibody as the detection antibody,
ensuring that they were only measuring antidrug antibodies.
Mazor et al11 adapted this method to measure antibodies to
ADA. Those authors described an incidence for ATA positivity
of 30.5%, which showed the sensitivity of anti-lambda chain
ELISA and its low rate of drug interference. However, in serum
with high levels of a drug, even anti-lambda chain ELISA is not
able to completely overcome drug interference.47 Anti-lambda
chain ELISA is also unable to detect anti-idiotypic antibodies,
i.e., antibodies that recognize functional binding epitopes.47
One way of overcoming drug interference is to perform
a prior acidic dissociation. Imaeda et al pretreated samples with
FIGURE 6. Therapeutic drug monitoring brought to light the factors inﬂuencing the loss of response.
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acid in both the IFX study and ADA study.6,29 In a previous work,
the authors showed the ability of this new method to detect ATIs
in samples containing detectable levels of IFX, which proved to
be more accurate than the bridging ELISA.48 From a total of 58
samples, the methodology by Imaeda et al could detect an addi-
tional 14 positive samples, of which, by the bridging ELISA, 8
had been considered negative and 6 “inconclusive.”
Three studies24,30,34 used the HMSA to measure ATIs, an
alternative assay to ELISA. The HMSA uses size exclusion high-
performance liquid chromatography.47 Although HMSA requires
expensive equipment, the authors of those studies state many
advantages, including the ability to overcome many potential ar-
tifacts encountered in the solid-phase ELISA, the ability to detect
high and low afﬁnity antibodies (low afﬁnity antibodies may not
be detected by ELISA due to multiple washing steps), the detec-
tion of all immunoglobulin isotypes and all IgG subclasses
(including IgG4), and the fact that it is not affected by substances
present in serum.49 However, a different ATI incidence was re-
ported by the 3 studies, which can be explained by differences in
the study population and sample size (Table 1).
Another assay is able to bridge the gaps of the ELISA
methodology. In ﬂuid-phase radioimmunoassay (RIA), used by
Steenholdt et al,35 a radio-labeled antibody to detect and quantify
the amount of antidrug antibodies is applied. It has proved to be
more sensitive than ELISA, as it is able to detect antidrug anti-
bodies in the presence of the drug and IgG4 isotype.40,41 More-
over, ﬂuid-phase RIA overcomes matrix effects encountered in
solid-phase assays due to epitope masking via protein aggrega-
tion. The major limitation of RIA is the need for advanced labo-
ratory facilities.47
Therefore, the differences in methodology, study design,
and sample size and characteristics may also explain why the 4
studies with IFX22,34,35,37 that performed an ROC curve analysis in
order to ﬁnd a cutoff level of antidrug antibodies related with
a clinical outcome found different threshold levels. It is also not
easy to compare the thresholds between studies because they used
different units (U/mL; mg/mL; ng/mL) and deﬁned different end-
points. A serious limitation of all of the studies was the inability to
show whether or not antidrug antibodies were neutralizing.
It is important to address whether or not antidrug antibodies
are functional, because we know that antidrug antibody detection
in serum does not always correlate with loss of clinical
response.47,50 Moreover, sometimes the presence of antidrug anti-
bodies may actually increase the half-life of the drug; if 1 or 2, but
not more, antidrug antibodies bind to the drug, the complex will
bind to Neonatal fragment crystallizable receptor and will escape
elimination.51 A study comparing different methodologies (ELI-
SA, EIA, RGA, RIA) to measure antidrug antibody levels has
been published and concluded that the ability to detect anti-
ATIs is comparable with respect to basic analytical properties.
ELISA and RIA showed a good correlation (R2 ¼ 0.73, P ¼
0.03), but the agreement was not so good, with a mean titer
difference of 22400 (25000 to 200), which can be partially
explained by the inability of bridging ELISA to detect IgG4
antidrug antibodies. The authors suggest that clinicians should
choose an assay where assessments take place in ﬂuid phase
and where all anti-IFX IgG isotypes are quantiﬁed.40
CONCLUSION
Currently, there is no doubt that drug levels correlate with
clinical and endoscopic outcomes, and this knowledge is the basis
of drug monitoring. Nevertheless, it can only be widely used in
clinical practice when there is a consensus on the thresholds of
drug and antidrug antibody levels that correlate with a speciﬁc
clinical outcome, including either clinical remission or loss of
response. Concerning drug level monitoring, any methodology is
adequate but the data published by now is insufﬁcient to come up
with a cutoff level. With respect to antidrug antibody levels,
assays have signiﬁcantly different sensitivity, therefore it will be
necessary to deﬁne a gold standard method or to establish
different cutoff levels for different methodologies.
REFERENCES
1. Colombel JF, Sandborn WJ, Reinisch W, et al. Inﬂiximab, azathio-
prine, or combination therapy for Crohn’s disease. N Engl J Med.
2010;362:1383–1395.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance inﬂiximab
for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:
1541–1549.
3. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Inﬂiximab for induction
and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;
353:2462–2476.
4. Peters CP, Eshuis EJ, Toxopeüs FM, et al. Adalimumab for Crohn’s
disease: long-term sustained beneﬁt in a population-based cohort of 438
patients. J Crohns Colitis. 2014;8:866–875.
5. García-Bosch O, Gisbert JP, Cañas-Ventura A, et al. Observational study
on the efﬁcacy of adalimumab for the treatment of ulcerative colitis and
predictors of outcome. J Crohns Colitis. 2013;7:717–722.
6. Imaeda H, Bamba S, Takahashi K, et al. Relationship between serum
inﬂiximab trough levels and endoscopic activities in patients with Crohn’s
disease under scheduled maintenance treatment. J Gastroenterol. 2014;49:
674–682.
7. Seow CH, Newman A, Irwin SP, et al. Trough serum inﬂiximab: a pre-
dictive factor of clinical outcome for inﬂiximab treatment in acute ulcer-
ative colitis. Gut. 2010;59:49–54.
8. Marits P, Landucci L, Sundin U, et al. Trough s-inﬂiximab and antibodies
towards inﬂiximab in a cohort of 79 IBD patients with maintenance in-
ﬂiximab treatment. J Crohns Colitis. 2014;8:881–889.
9. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to inﬂiximab on
clinical outcomes and serum inﬂiximab levels in patients with inﬂamma-
tory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108:
40–47.
10. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of inﬂix-
imab is the F(ab’)2, but measuring antibodies to the intact inﬂiximab
molecule is more clinically useful. Gut. 2011;60:41–48.
11. Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody
levels as predictors of clinical and laboratory response in patients with
Crohn’s disease. Aliment Pharmacol Ther. 2014;40:620–628.
12. Felice C, Marzo M, Pugliese D, et al. Therapeutic drug monitoring of anti-
TNF-a agents in inﬂammatory bowel diseases. Expert Opin Biol Ther.
2015;15:1107–1117.
13. Yarur AJ, Abreu MT, Deshpande AR, et al. Therapeutic drug monitoring
in patients with inﬂammatory bowel disease. World J Gastroenterol.
2014;20:3475–3484.
14. Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels
and disease activity. Nat Rev Gastroenterol Hepatol. 2014;11:243–255.
15. Ben-Horin S. Loss of response to anti-tumor necrosis factors: what is the
next step?. Dig Dis. 2014;32:384–388.
Silva-Ferreira et al Inﬂamm Bowel Dis  Volume 0, Number 0, Month 2016
12 | www.ibdjournal.org
Copyright © 2016 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
16. Bendtzen K. Immunogenicity of anti-TNF-a Biotherapies: I. Individual-
ized Medicine based on Immunopharmacological evidence. Front Immu-
nol. 2015;6:152.
17. Khanna R, Sattin BD, Aﬁf W, et al. Review article: a clinician’s guide for
therapeutic drug monitoring of inﬂiximab in inﬂammatory bowel disease.
Aliment Pharmacol Ther. 2013;38:447–459.
18. Pallagi-Kunstár É, Farkas K, Szepes Z, et al. Utility of serum TNF-a,
inﬂiximab trough level, and antibody titers in inﬂammatory bowel disease.
World J Gastroenterol. 2014;20:5031–5035.
19. Vande Casteele N, Feagan B, Gils A, et al. Therapeutic drug monitoring in
inﬂammatory bowel disease: current state and future perspectives. Curr
Gastroenterol Rep. 2014;16:1–8.
20. Altwegg R, Vincent T. TNF blocking therapies and immunomonitoring in
patients with inﬂammatory bowel disease.Mediators Inﬂamm. 2014;2014:
172821.
21. Stroup D, Berlin J, Morton S, et al. Meta-analysis of observational
studies in epidemiology: a proposal for reporting. Meta-analysis of
Observational Studies in Epidemiology (MOOSE) group. JAMA.
2000;283:2008–2012.
22. Vande Casteele N, Khanna R, Levesque BG, et al. The relationship
between inﬂiximab concentrations, antibodies to inﬂiximab and disease
activity in Crohn’s disease. Gut. 2015;64:1539–1545.
23. Zittan E, Kabakchiev B, Milgrom R, et al. Higher adalimumab drug levels
are associated with mucosal healing in patients with Crohn’s disease.
J Crohns Colitis. 2016;10:510–515.
24. Singh N, Rosenthal CJ, Melmed GY, et al. Early inﬂiximab trough levels
are associated with persistent remission in pediatric patients with inﬂam-
matory bowel disease. Inﬂamm Bowel Dis. 2014;20:1708–1713.
25. Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between
serum concentration of inﬂiximab and efﬁcacy in adult patients with
ulcerative colitis. Gastroenterology. 2014;147:1296–1307.e5.
26. Bortlik M, Duricova D, Malickova K, et al. Inﬂiximab trough levels may
predict sustained response to inﬂiximab in patients with Crohn’s disease.
J Crohns Colitis. 2013;7:736–743.
27. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum inﬂix-
imab trough level and decrease of C-reactive protein level are associated
with durable sustained response to inﬂiximab: a retrospective analysis of
the ACCENT I trial. Gut. 2014;63:1721–1727.
28. Echarri A, Ferreiro R, Fraga R, et al. Impact of postinduction inﬂiximab
trough level and disease activity on primary response in Crohn’s Disease.
J Crohns Colitis. 2015;9:S342–S343.
29. Imaeda H, Takahashi K, Fujimoto T, et al. Clinical utility of newly devel-
oped immunoassays for serum concentrations of adalimumab and anti-
adalimumab antibodies in patients with Crohn’s disease. J Gastroenterol.
2014;49:100–109.
30. Levesque BG, Greenberg GR, Zou G, et al. A prospective cohort study to
determine the relationship between serum inﬂiximab concentration and
efﬁcacy in patients with luminal Crohn’s disease. Aliment Pharmacol
Ther. 2014;39:1126–1135.
31. Papamichail K, Vande Casteele N, Billiet T, et al. Early therapeutic drug
monitoring for prediction of short-term mucosal healing in patients with
ulcerative colitis treated with inﬂiximab. Gastroenterology. 2015;148:
S848.
32. Roblin X, Duru G, Clavel L, et al. Faecal calprotectin measurement and
inﬂiximab trough levels predict therapeutic evolution CD patients in clin-
ical remission. Drug Levels & Biomarkers. 2015;148:S–853.
33. Tang J, Gao X, Zhi M, et al. Serum inﬂiximab levels and early mucosal
healing in Crohn’s disease. J Crohns Colitis. 2014;8:S209–S210.
34. Vande Casteele N, Gils A, Singh S, et al. Antibody response to inﬂiximab
and its impact on pharmacokinetics can be transient. Am J Gastroenterol.
2013;108:962–971.
35. Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic
accuracy of inﬂiximab trough levels and anti-inﬂiximab antibodies in
Crohn’s disease. Scand J Gastroenterol. 2011;46:310–318.
36. Roblin X, Marotte H, Rinaudo M, et al. Association between pharmaco-
kinetics of adalimumab and mucosal healing in patients with inﬂammatory
bowel diseases. Clin Gastroenterol Hepatol. 2014;12:80–84.e2.
37. Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of
inﬂiximab and mucosal healing in inﬂammatory bowel disease: a prospec-
tive study. Inﬂamm Bowel Dis. 2013;19:2568–2576.
38. Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNFalpha therapy: serum
levels of inﬂiximab and adalimumab associate with mucosal healing in pa-
tients with inﬂammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;
14:550–557.
39. Chiu YL, Rubin DT, Vermeire S, et al. Serum adalimumab concentration
and clinical remission in patients with Crohn’s disease. Inﬂamm Bowel
Dis. 2013;19:1112–1122.
40. Steenholdt C, Ainsworth MA, Tovey M, et al. Comparison of techniques
for monitoring inﬂiximab and antibodies against inﬂiximab in Crohn’s
Disease. Ther Drug Monit. 2013;35:530–538.
41. Vande Casteele N, Buurman DJ, Sturkenboom MGG, et al. Detection of
inﬂiximab levels and anti-inﬂiximab antibodies: a comparison of three
different assays. Aliment Pharmacol Ther. 2012;36:765–771.
42. Steenholdt C, Bendtzen K, Brynskov J, et al. Clinical implications of mea-
suring drug and anti-drug antibodies by different assays when optimizing
inﬂiximab treatment failure in Crohn’s disease. J Crohns Colitis. 2014;8:S291.
43. Moore C, Corbett G, Moss AC. Systematic review and meta-analysis:
serum inﬂiximab levels during maintenance therapy and outcomes in
inﬂammatory bowel disease. J Crohns Colitis. 2016;10:619–625.
44. D’Haens G, Vermeire S, Lambrecht G, et al. OP029 Drug-concentration
versus symptom-driven dose adaptation of inﬂiximab in patients with
active Crohn’s disease: a prospective, randomised, multicentre trial (Tai-
lorix). J Crohns Colitis. 2016;10:24.
45. Casteele NV, Gils A, Ballet V, et al. OP001 Randomised controlled trial
of drug level versus clinically based dosing of inﬂiximab maintenance
therapy in IBD: ﬁnal results of the TAXIT study. United Eur Gastro-
enterol J. 2013:A1–A134.
46. Kopylov U, Mazor Y, Yavzori M, et al. Clinical utility of antihuman
lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus
double antigen ELISA for the detection of anti-inﬂiximab antibodies.
Inﬂamm Bowel Dis. 2012;18:1628–1633.
47. Bendtzen K. Personalized medicine: theranostics (therapeutics diagnos-
tics) essential rational use tumor necrosis factor-alpha antagonists. Discov
Med. 2013;15:201–211.
48. Imaeda H, Andoh A, Fujiyama Y. Development of a new immunoassay
for the accurate determination of anti-inﬂiximab antibodies in inﬂamma-
tory bowel disease. J Gastroenterol. 2012;47:136–143.
49. Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation
of a homogeneous mobility shift assay for the measurement of inﬂiximab
and antibodies-to-inﬂiximab levels in patient serum. J Immunol Methods.
2012;382:177–188.
50. Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of anti-
drug antibodies in patients with inﬂammatory bowel disease treated with
inﬂiximab. Gut. 2014;63:1258–1264.
51. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinet-
ics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548–558.
Inﬂamm Bowel Dis  Volume 0, Number 0, Month 2016 Inﬂiximab and Adalimumab Drug Monitoring
www.ibdjournal.org | 13
Copyright © 2016 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
Inflammatory Bowel Diseases 
Instructions for Authors 
 
SCOPE 
The focus of the journal Inflammatory Bowel Diseases® is to bring the most current 
information in the clinical and basic sciences to all physicians caring for patients with 
inflammatory bowel diseases, and to investigators performing research in inflammatory 
bowel diseases and related fields. The journal publishes peer-reviewed manuscripts and 
review articles in basic and clinical sciences, updates on clinical trials, reviews of the current 
literature, editorials, and other features. 
ETHICAL/LEGAL CONSIDERATIONS 
A submitted manuscript must be an original contribution not previously published (except as 
an abstract or preliminary report), must not be under consideration for publication 
elsewhere, and, if accepted, must not be published elsewhere in similar form, in any 
language, without the consent of the publisher. Each person listed as an author is expected 
to have participated in the study to a significant extent. Although the editors and referees 
make every effort to ensure the validity of published manuscripts, the final responsibility 
rests with the authors, not with the journal, its editors, or the publisher. All manuscripts 
must be submitted through the journal's online submission system 
at http://www.editorialmanager.com/ibd/. 
Inflammatory Bowel Diseases utilizes the plagiarism software, CrossCheck. Manuscripts 
submitted to this journal may be screened for plagiarism against previously published works. 
Authors who have been found to be guilty of plagiarism after the appropriate institutional 
investigation will be banned from submitting to the journal for a defined period of time. 
Patient Anonymity and Informed Consent - It is the author's responsibility to ensure 
that a patient's anonymity be carefully protected and to verify that any experimental 
investigation with human subjects reported in the manuscript was performed with informed 
consent and following all the guidelines for experimental investigation with human subjects 
required by the institution(s) with which all the authors are affiliated. Authors should mask 
patients' eyes and remove patients' names from figures unless they obtain written consent 
from the patients and submit written consent with the manuscript. 
Human Studies - Human experimentation must conform to ethical standards, and be 
approved by the appropriate Institutional Review Board (IRB). A statement concerning IRB 
approval and consent procedures must appear at the beginning of the Methods section. Any 
systematic data gathering effort in patients or volunteers must be approved by an IRB or 
adhere to appropriate local/national regulations. The Editors of Inflammatory Bowel 
Diseases are concerned about appropriate IRB review and informed consent. Authors may be 
questioned about the details of consent forms or the consent process. On occasion, the 
Editor-in-Chief may request a copy of the approved IRB application from the author. Lack of 
appropriate consent or documentation may be grounds for rejection. Local IRB approval does 
not guarantee acceptability; the final decision will be made by the Editor-in-Chief. 
Animal Studies - Experimental work on animals must conform to the guidelines laid out in 
the Guide for the Care and Use of Laboratory Animals, which is available from the National 
Academy of Science; a text-only version is available 
at http://www.nap.edu/readingroom/books/labrats/. Adherence to all relevant regulations 
and/or approval of the appropriate institutional Animal Care Committee or governmental 
licensure of the investigator and/or laboratory must be obtained. A statement concerning 
such approval must be included at the beginning of the Methods section. The Editors 
of Inflammatory Bowel Diseases are concerned about appropriate animal care. On occasion, 
the Editor-in-Chief may request a copy of the approved Animal Care Committee application 
from the author. Local committee approval does not guarantee acceptability; the final 
decision will be made by the Editor-in-Chief. 
Registration of Clinical Trials - All clinical trials that involve investigational drugs 
supported by a pharmaceutical firm or investigational devices supported by a device 
manufacturer must be registered at the time that a manuscript is submitted to Inflammatory 
Bowel Diseases for publication. The registry and registration number must be stated in the 
first paragraph of the Methods section of the manuscript. 
Compliance with NIH and Other Research Funding Agency Accessibility 
Requirements - A number of research funding agencies now require or request authors to 
submit the post-print (the article after peer review and acceptance but not the final 
published article) to a repository that is accessible online by all without charge. As a service 
to our authors, LWW will identify to the National Library of Medicine (NLM) articles that 
require deposit and will transmit the post-print of an article based on research funded in 
whole or in part by the National Institutes of Health, Wellcome Trust, Howard Hughes 
Medical Institute, or other funding agencies to PubMed Central. The revised Copyright 
Transfer Agreement & Disclosure form provides the mechanism. 
Copyright - All authors must complete and submit the journal's copyright transfer 
agreement, which includes a section on the disclosure of potential conflicts of interest based 
on the recommendations of the International Committee of Medical Journal Editors, "Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals" 
(www.icmje.org/update.html).   
A copy of the form is made available to the submitting author within the Editorial Manager 
submission process.  Co-authors will automatically receive an Email with instructions on 
completing the form upon submission. 
Conflicts of Interest - Authors must state all possible conflicts of interest in the 
manuscript, including financial, consultant, institutional and other relationships that might 
lead to bias or a conflict of interest. If there is no conflict of interest, this should also be 
explicitly stated as none declared. All sources of funding should be acknowledged in the 
manuscript. All relevant conflicts of interest and sources of funding should be included on the 
title page of the manuscript with the heading "Conflicts of Interest and Source of Funding". 
For example: Conflicts of Interest and Source of Funding: A has received honoraria from 
Company Z. B is currently receiving a grant (#12345) from Organization Y, and is on the 
speaker's bureau for Organization X — the CME organizers for Company A. For the remaining 
authors none were declared. 
In addition, each author must complete and submit the journal's copyright transfer 
agreement, which includes a section on the disclosure of potential conflicts of interest based 
on the recommendations of the International Committee of Medical Journal Editors, "Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals" 
(www.icmje.org/update.html). 
A copy of the form is made available to the submitting author within the Editorial Manager 
submission process.  Co-authors will automatically receive an Email with instructions on 
completing the form upon submission. 
Permissions - Authors must submit written permission from the copyright owner (usually 
the publisher) to use direct quotations, tables, or illustrations that have appeared in 
copyrighted form elsewhere, along with complete details about the source. Any permissions 
fees that might be required by the copyright owner are the responsibility of the authors 
requesting use of the borrowed material, and not the responsibility of the publisher. 
PREPARATION OF MANUSCRIPT 
Manuscripts that do not adhere to the following instructions will be returned to the 
corresponding author for technical revision before undergoing peer review. See specific 
guidelines for Letters to the Editor below. For questions on preparing manuscripts for 
submission, please contact Meghann Knowles at meghann@jjeditorial.com. 
Title Page Include on the title page (a) complete manuscript title; (b) authors' full names, 
highest academic degrees, and affiliations; (c) name and address for correspondence, 
including fax number, telephone number, and e-mail address; and (d) sources of support 
that require acknowledgment. 
The title page must also include disclosure of funding received for this work from any of the 
following organizations: National Institutes of Health (NIH); Wellcome Trust; Howard Hughes 
Medical Institute (HHMI); and other(s). 
Structured Abstract and Key Words Limit the abstract to 250 words. It must be factual 
and comprehensive. Do not cite references in the abstract. Limit the use of abbreviations and 
acronyms, and avoid general statements (e.g., "the significance of the results is discussed"). 
It should be sectioned into Background, Methods, Results, and Conclusions. List three to five 
key words. 
Text For full-length research articles, organize the manuscript in the following sequence: 
Abstract and Key Words, Introduction, Materials and Methods, Ethical Considerations, 
Results, Discussion, Acknowledgment, References, Tables, and Figure Legends. Original 
Research Articles: Authors are encouraged to submit articles in basic or clinical science. 
Review Articles of exceptional merit will also be accepted. Contributors should communicate 
with the Editors before submitting a review. Abbreviations must be defined at first mention in 
text and in each table and figure. If a brand name is cited, manufacturer and address (city 
and state/country) should be supplied. Acknowledge all forms of support, including 
pharmaceutical industry support, in an Acknowledgment paragraph. 
Abbreviations For a list of standard abbreviations, consult the Council of Biology Editors 
Style Guide (available from the Council of Science Editors, 9650 Rockville Pike, Bethesda, MD 
20814) or other standard sources. Write out the full term for each abbreviation at its first 
use unless it is a standard unit of measure. 
References The authors are responsible for the accuracy of the references. Key the 
references (double-spaced) at the end of the manuscript. Cite the references in text in the 
order of appearance, including those references cited in tables and figure legends at the 
chronological citation of the tables and figures in text. Cite unpublished data, such as papers 
submitted but not yet accepted for publication, personal communications, in parentheses in 
the text. If there are more than three authors, only name the first three authors and then 
use et al. For abbreviations of journal names, refer to List of Journals Indexed in Index 
Medicus. This can be accessed at http://www.nlm.nih.gov/tsd/serials/lji.html. 
Sample references are given below: 
Journal Article 
1. Gudlaugsdottir S, van Dekken H, Stijnen T, et al. Prolonged use of proton pump inhibitors, 
CagA status, and the outcome of Helicobacter pylori gastritis. J Clin Gastroenterol. 
2002;34:536-540. 
Book Chapter 
2. Tobin RW, Kimmey MB. Painful diseases of the gastrointestinal tract. In: Loeser JD, 
ed. Bonica's Management of Pain. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 
2001:1269-1292. 
Entire Book  
3. Rohen JW, Yokochi C, Lütjen-Drecoll E. Color Atlas of Anatomy: A Photographic Study of 
the Human Body. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002. 
Software  
4. Epi Info [computer program]. Version 6. Atlanta: Centers for Disease Control and 
Prevention; 1994. 
Online Journals  
5. Friedman SA. Preeclampsia: a review of the role of prostaglandins. ObstetGynecol [serial 
online]. January 1988;71:22-37. Available from: BRS Information Technologies, McLean, VA. 
Accessed December 15, 1990. 
Database  
6. CANCERNET-PDQ [database online]. Bethesda, MD: National Cancer Institute; 2014. 
Updated March 29, 2014. 
World Wide Web  
7. Gostin LO. Drug use and HIV/AIDS [JAMA HIV/AIDS Web site]. June 1, 2015. Available 
at: http://www.ama-assn.org/special/hiv/ethics,. Accessed July 26, 2015. 
Figures Art should be created/scanned and saved and submitted as either a TIFF (tagged 
image file format), or an EPS (encapsulated postscript) file. Line art must have a resolution 
of at least 1200 dpi (dots per inch), and electronic photographs, radiographs, CT scans, and 
other scanned images must have a resolution of at least 300 dpi. If fonts are used in the 
artwork, they must be converted to paths or outlines or they must be embedded in the files. 
Color images must be created/scanned and saved and submitted as CMYK files. Please note 
that artwork generated from office suite programs such as Corel Draw and MS Word and 
artwork downloaded from the Internet (JPEG or GIF files) cannot be used. Cite figures 
consecutively in the manuscript, and number them in the order in which they are discussed. 
Figure Legends Legends must be submitted for all figures. They should be brief and 
specific, and they should appear after the tables. Use scale markers in the image for electron 
micrographs, and indicate the type of stain used. 
Color Figures At no cost to the author, the journal accepts for publication color figures that 
will enhance the article. Figures are also published online in color at no cost. 
Steps for Submitting Artwork  
 
1. Please reference "5 Steps to Creating Digital Artwork (pdf)" available 
at http://edmgr.ovid.com/lww-final/accounts/5StepsforArt.pdf, specifically steps 2 and 3, 
when creating figures for submission.  
 
2. Create, Scan and Save according to the "5 Steps to Creating Digital Artwork (pdf)".  
 
3. Compare your final figure to the Target Digital-Imaging Results listed below.  
 
4. Upload each figure to the journal's online submission system in conjunction with your 
manuscript text and tables. 
Digital Artwork Guideline Checklist 
Here are the basics to have in place before submitting your digital art to Inflammatory Bowel 
Diseases. Artwork saved as TIFF and EPS files. Do not save TIFFs as compressed files. 
PowerPoint files are also acceptable. 
 Artwork created as the actual size (or slightly larger) it will appear in the journal. (To 
get an idea of the size images should be when they print, study a copy of the journal 
to which you wish to submit. Measure the artwork typically shown and scale your 
image to match.) 
 Crop out any white or black space surrounding the image. 
 Text and fonts in any figure are one of the acceptable fonts: Helvetica, Times 
Roman, Symbol, Mathematical PI, and European PI. 
 Color images are created/scanned and saved and submitted as CMYK only. Do not 
submit any figures in RGB mode because RGB is the color mode used for 
screens/monitors and CMYK is the color mode used for print. 
 Line art saved at a resolution of at least 1200 dpi. 
 Images saved at a resolution of at least 300 dpi. 
 Each figure saved as a separate file and saved separately from the accompanying 
text file. 
 For multi-panel or composite figures only: Any figure with multiple parts should be 
sent as one file with each part labeled the way it is to appear in print. 
Remember: 
 Artwork generated from office suite programs such as CorelDRAW, MS Word, Excel, 
and artwork downloaded from the Internet (JPEG or GIF files) cannot be used 
because the quality is poor when printed. 
 Cite figures consecutively in your manuscript. 
 Number figures in the figure legend in the order in which they are discussed. 
 Upload figures consecutively to the journal's online submission system and number 
figures consecutively in the Description box during upload. 
Tables Create tables using the table creating and editing feature of your word processing 
software (e.g., Word). Do not use Excel or comparable spreadsheet programs. Do not submit 
tables as image files or images placed in Word documents, tables must be provided as 
editable text (Word files are preferred). Submit all tables as separate files. Cite tables 
consecutively in the text, and number them in that order. Key each on a separate sheet, and 
include the table title, appropriate column heads, and explanatory legends (including 
definitions of any abbreviations used). Do not imbed tables within the body of the 
manuscript. They should be self-explanatory and should supplement, rather than duplicate, 
the material in the text. 
Supplemental Digital Content (SDC) Authors may submit supplementary materials via 
the journal's online submission system that enhance their article's text to be considered for 
online posting. SDC may include standard media such as text documents, graphs, audio, 
video, etc. On the Attach Files page of the submission process, please select Supplemental 
Audio, Video, or Data for your uploaded file as the Submission Item. If an article with SDC is 
accepted, our production staff will create a URL with the SDC file. The URL will be placed in 
the call-out within the article. SDC files are not copy-edited by LWW staff, they will be 
presented digitally as submitted. Please supply the SDC files as you would like them to 
appear in final publication (include legends in the same file as the images; make text double 
spaced or single spaced per your preference). For a list of all available file types and detailed 
instructions, please visit http://links.lww.com/A142. 
SDC Call-outs Supplemental Digital Content must be cited consecutively in the text of the 
submitted manuscript. Citations should include the type of material submitted (Audio, Figure, 
Table, etc.), be clearly labeled as "Supplemental Digital Content," include the sequential list 
number, and provide a description of the supplemental content. All descriptive text should be 
included in the call-out as it will not appear elsewhere in the article. 
Example: We performed many tests on the degrees of flexibility in the elbow (see Video, 
Supplemental Digital Content 1, which demonstrates elbow flexibility) and found our results 
inconclusive. 
List of Supplemental Digital Content A listing of Supplemental Digital Content must be 
submitted at the end of the manuscript file. Include the SDC number and file type of the 
Supplemental Digital Content. This text will be removed by our production staff and not be 
published. 
Example:  
Supplemental Digital Content 1.wmv 
SDC Files Requirements All acceptable file types are permissible up to 10 MBs. For audio 
or video files greater than 10 MBs, authors should first query the journal office for approval. 
For a list of all available file types and detailed instructions, please 
visit http://links.lww.com/A142. 
Style Follow American Medical Association Manual of Style (10th edition). Stedman's Medical 
Dictionary (27th edition) and Merriam Webster's Collegiate Dictionary (10th edition) should 
be used as standard references. Refer to drugs and therapeutic agents by their accepted 
generic or chemical names, and do not abbreviate them. Use code numbers only when a 
generic name is not yet available. In that case, supply the chemical name and a figure giving 
the chemical structure of the drug. Capitalize the trade names of drugs and place them in 
parentheses after the generic names. To comply with trademark law, include the name and 
location (city and state in USA; city and country outside USA) of the manufacturer of any 
drugs, supplies, or equipment mentioned in the manuscript. Use the metric system to 
express units of measure and degrees Celsius to express temperatures, and use SI units 
rather than conventional units. 
Basic and Clinical IBD Review Articles Guidelines Basic and clinical IBD Review articles 
should present recent advances in a relatively narrow topic that have been made in cutting 
edge research. 
The goal of the basic and clinical IBD review articles should be to present a complete 
summary of important research areas that are now improving our understanding of Crohn's 
disease and ulcerative colitis. 
The body of basic and clinical IBD Review articles should be no longer than 20 double spaced 
pages (not including references, figures, and tables). There should be no more than 6 tables 
and figures (combined). Supplemental figures and tables will be allowed online. If page limits 
need to be increased, the authors may request permission from the Editors to increase the 
length of the Review article. The number of references should be limited to 100. The Review 
article should be focused on a single specific topic. All review articles will be peer-reviewed. 
Future Directions and Methods for IBD Research Guidelines Original research articles 
and review articles on future directions and methods for IBD research should discuss 
important basic and clinical areas in which investigators should focus their efforts to provide 
a deeper understanding of IBD research areas in which rapid advances and novel concepts 
can be made. In addition, the Future Directions and Methods for IBD original research 
articles and review articles should include a discussion of areas in which improved 
methodologic tools have been identified and exactly how those methods should be 
performed. Basic science directions and methods should be presented that will expand our 
knowledge of areas that will allow novel insights to be made regarding the genetic, 
immunologic, microbial and environmental interactions that are the basis of the pathogenesis 
of Crohn's disease and ulcerative colitis. Clinical directions and methods should be presented 
that will allow investigators to make advances using cohort studies, multicenter registries, 
risk stratifications, and treatment outcomes. The goal of the Future Directions and Methods 
for clinical IBD original research articles and review articles should be to better understand 
the challenging biological variables in IBD patients and to provide optimal evidence of novel 
therapeutics that will more effectively treat, cure, and prevent Crohn's disease and ulcerative 
colitis. 
Original research articles, for the Future Directions and Methods for IBD research section, 
should be written as described in the IBD Journal Instructions for original research articles. 
Review articles, for the Future Directions and Methods for IBD research section, should be no 
longer than 35 double spaced pages (including references and figure legends). There should 
be no more than 6 tables and figures (combined). Supplemental figures and tables will be 
allowed online. If page limits need to be increased, the authors may request permission from 
the Editors to increase the length of their future directions and methods for IBD research 
review article. The number of references should be limited to 100. The future directions and 
methods for IBD research review article should be focused on a single specific topic. 
Letters to the Editor Guidelines Letters in response to articles published in the journal are 
welcome and should be submitted via IBD's online submission system. All Letters should 
start with the phrase "To the Editors," and be written as a letter. Letters must be submitted 
the end of the following calendar month (e.g. by the end of July, for letters referring to 
articles in the June print issue) and be a maximum of 400 words, with no more than one 
figure or table and no more than 5 references. All LTEs will be published online-only. 
Research letters and case-based discussions will no longer be accepted for submission 
effective November 1, 2012. 
REVISIONS 
When submitting a revision, please submit both a clean copy and marked copy of the 
manuscript. The marked copy should highlight all of the changes made the by authors after 
the original review. Authors can use the track changes feature of the Microsoft Word 
program to create a marked copy. Authors also should submit all tables and figures in 
separate files for production purposes. 
AFTER ACCEPTANCE 
Open access LWW's hybrid open access option is offered to authors whose articles have 
been accepted for publication. With this choice, articles are made freely available online 
immediately upon publication. Authors may take advantage of the open access option at the 
point of acceptance to ensure that this choice has no influence on the peer review and 
acceptance process. These articles are subject to the journal's standard peer-review process 
and will be accepted or rejected based on their own merit. 
Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual 
unrestricted online access to their published article to readers globally, immediately upon 
publication. The article processing charge for Inflammatory Bowel Diseases is $3,000. The 
article processing charge for authors funded by the Research Councils UK (RCUK) is $3,800. 
The publication fee is charged on acceptance of the article and should be paid within 30 days 
by credit card by the author, funding agency or institution. Payment must be received in full 
for the article to be published open access. 
 Authors retain copyright Authors retain their copyright for all articles they opt to 
publish open access. Authors grant LWW a license to publish the article and identify 
itself as the original publisher. 
 Creative Commons license Articles opting for open access will be freely available 
to read, download and share from the time of publication. Articles are published 
under the terms of the Creative Commons License Attribution-NonCommerical No 
Derivative 3.0 which allows readers to disseminate and reuse the article, as well as 
share and reuse of the scientific material. It does not permit commercial exploitation 
or the creation of derivative works without specific permission. To view a copy of this 
license visit: http://creativecommons.org/licenses/by-nc-nd/3.0. 
 Compliance with NIH, RCUK, Wellcome Trust and other research funding 
agency accessibility requirements A number of research funding agencies now 
require or request authors to submit the post-print (the article after peer review and 
acceptance but not the final published article) to a repository that is accessible online 
by all without charge. As a service to our authors, LWW identifies to the National 
Library of Medicine (NLM) articles that require deposit and transmits the post-print of 
an article based on research funded in whole or in part by the National Institutes of 
Health, Howard Hughes Medical Institute, or other funding agencies to PubMed 
Central. The revised Copyright Transfer Agreement provides the mechanism. LWW 
ensures that authors can fully comply with the public access requirements of major 
funding bodies worldwide. Additionally, all authors who choose the open access 
option will have their final published article deposited into PubMed Central. RCUK and 
Wellcome funded authors can choose to publish their paper as open access with the 
payment of an article process charge (gold route), or opt for their accepted 
manuscript to be deposited (green route) into PMC with an embargo. With both the 
gold and green open access options, the author will continue to sign the Copyright 
Transfer Agreement (CTA) as it provides the mechanism for LWW to ensure that the 
author is fully compliant with the requirements. After signature of the CTA, the 
author will then sign a License to Publish where they will then own the copyright. 
Those authors who wish to publish their article via the gold route will be able to 
publish under the terms of the Attribution 3.0 (CCBY) License. To view of a copy of 
this license visit: http://creativecommons.org/licenses/by/2.0/. Those authors who 
wish to publish their article via the green route will be able to publish under the 
rights of the Attribution Non-commercial 3.0 (CCBY NC) license 
(http://creativecommons.org/licenses/by-nc/2.0/). It is the responsibility of the 
author to inform the Editorial Office and/or LWW that they have RCUK funding. LWW 
will not be held responsible for retroactive deposits to PMC if the author has not 
completed the proper forms. 
FAQ for open access http://links.lww.com/LWW-ES/A48 
Page Proofs and Corrections - Corresponding authors will receive an e-mail containing a 
link to the electronic page proofs to check the copyedited and typeset article before 
publication. The pages proofs are provided as portable document format (PDF) files which 
require Adobe Reader to be viewed and edited. Complete instructions will be provided with 
the e-mail for downloading the files and for returning the corrected pages electronically to 
the publisher. It is the author's responsibility to ensure that there are no errors in the proofs. 
Changes that have been made to conform to journal style should be allowed to stand if they 
do not alter the authors' meaning. Authors may be charged for alterations to the proofs 
beyond those required to correct errors or to answer queries. Proofs must be checked 
carefully and corrections returned within 24 to 48 hours of receipt, as requested in the 
communication accompanying the page proofs. 
Reprints - The corresponding author will receive the reprint order form via e-mail while the 
article is in production. Reprint requests can be submitted any time before or after 
publication of the article. For orders submitted before the article is published, the reprints 
are normally shipped 6 to 8 weeks after publication of the issue in which the item appears. 
For any questions regarding reprints or publication fees, contact the Reprint Department by 
mail at Lippincott Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201; by 
phone at 1-800-341-2258; by fax at 410-528-4434; or by e-mail 
at: reprints@wolterskluwer.com. 
Permissions - For permission and/or rights to use content for which the copyright holder is 
LWW or the society, please go to the journal's website and after clicking on the relevant 
article, click on the "Request Permissions" link under the "Article Tools" box that appears on 
the right side of the page. Alternatively, send an e-mail to customercare@copyright.com. 
For Translation Rights & Licensing queries, contact Silvia Serra, Translations Rights, 
Licensing & Permissions Manager, Wolters Kluwer Health (Medical Research) Ltd, 250 
Waterloo Road, London SE1 8RD, UK. Phone: +44 (0) 207 981 0600. E-
mail: silvia.serra@wolterskluwer.com 
For Special Projects and Reprints (U.S./Canada), contact Alan Moore, Director of Sales, 
Lippincott Williams & Wilkins, Two Commerce Square, 2001 Market Street, Philadelphia, PA 
19103. Phone: 215-521-8638. E-mail: alan.moore@wolterskluwer.com 
For Special Projects and Reprints (non-U.S./Canada), contact Silvia Serra, Translations 
Rights, Licensing & Permissions Manager, Wolters Kluwer Health (Medical Research) Ltd, 250 
Waterloo Road, London SE1 8RD, UK. Phone: +44 (0) 207 981 0600. E-
mail: silvia.serra@wolterskluwer.com 
 
  
 
Agradecimentos 
 
    
 
Ao meu orientador, Professor Doutor Fernando Magro, pela 
oportunidade de trabalhar com ele e pela disponibilidade ao longo 
de todo o trabalho. 
À Eng. Joana Afonso, pelo apoio incansável e por todo o carinho. 
 
 
 
